Lemborexant - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for lemborexant and what is the scope of patent protection?
Lemborexant
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lemborexant has fifty-three patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for lemborexant
International Patents: | 53 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 38 |
Clinical Trials: | 24 |
Patent Applications: | 19 |
What excipients (inactive ingredients) are in lemborexant? | lemborexant excipients list |
DailyMed Link: | lemborexant at DailyMed |
Recent Clinical Trials for lemborexant
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Eisai Co., Ltd. | Phase 2 |
Baylor College of Medicine | Phase 3 |
University of California, San Francisco | Phase 4 |
Pharmacology for lemborexant
Drug Class | Orexin Receptor Antagonist |
Mechanism of Action | Cytochrome P450 2B6 Inducers Orexin Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for lemborexant
US Patents and Regulatory Information for lemborexant
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lemborexant
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2626350 | COMPOSÉ DE CYCLOPROPANE (CYCLOPROPANE COMPOUND) | See Plans and Pricing |
Tunisia | 2013000119 | CYCLOPROPANE COMPOUNDS | See Plans and Pricing |
Singapore | 188585 | CYCLOPROPANE COMPOUND | See Plans and Pricing |
Russian Federation | 2017112308 | КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ БЕССОННИЦЫ | See Plans and Pricing |
Morocco | 34609 | COMPOSÉ DE CYCLOPROPANE | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.